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Abstract
Background: Chemotherapy resistance presents a difficult challenge in treating epithelial ovarian cancer patients,
particularly when tumors exhibit resistance to multiple chemotherapeutic agents. A few studies have shown that
elevated serum levels of the ovarian cancer biomarker HE4 correlate with tumor chemoresistance, response to
treatment, and survival. Here, we sought to confirm our previous results that HE4 contributes to collateral resistance
to cisplatin and paclitaxel in vitro and uncover factors that may contribute to HE4-mediated chemoresistance.
Methods: MTS assays and western blots for cleaved PARP were used to assess resistance of HE4-overexpressing
SKOV3 and OVCAR8 clones to cisplatin and paclitaxel. CRISPR/Cas technology was used to knockdown HE4 in
HE4-overexpressing SKOV3 cells. A microarray was conducted to determine differential gene expression between
SKOV3 null vector-transfected and HE4-overexpressing clones upon cisplatin exposure, and results were validated
by quantitative RT-PCR. Regulation of mitogen activated protein kinases (MAPKs) and tubulins were assessed by
western blot.
Results: HE4-overexpressing SKOV3 and OVCAR8 clones displayed increased resistance to cisplatin and paclitaxel.
Knockdown of HE4 in HE4-overexpressing SKOV3 cells partially reversed chemoresistance. Microarray analysis revealed
that HE4 overexpression resulted in suppression of cisplatin-mediated upregulation of EGR1, a MAPK-regulated gene
involved in promoting apoptosis. Upregulation of p38, a MAPK activated in response to cisplatin, was suppressed
in HE4-overexpressing clones. No differences in extracellular signal-regulated kinase (ERK) activation were noted in
HE4-overexpressing clones treated with 25 μM cisplatin, but ERK activation was partially suppressed in HE4-overexpressing
clones treated with 80 μM cisplatin. Furthermore, treatment of cells with recombinant HE4 dramatically affected ERK
activation in SKOV3 and OVCAR8 wild type cells. Recombinant HE4 also upregulated α-tubulin and β-tubulin levels in
SKOV3 and OVCAR8 cells, and microtubule associated protein tau (MAPT) gene expression was increased in SKOV3
HE4-overexpressing clones.
Conclusions: Overexpression of HE4 promotes collateral resistance to cisplatin and paclitaxel, and downregulation of
HE4 partially reverses this chemoresistance. Multiple factors could be involved in HE4-mediated chemoresistance,
including deregulation of MAPK signaling, as well as alterations in tubulin levels or stability.
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Background
Chemotherapy resistance is a challenging problem in the
treatment of epithelial ovarian cancer (EOC) patients.
While a majority (80 %) of women initially responds to
first-line platinum/taxane chemotherapy, recurrent dis-
ease presents in 60–85 % of patients, and is fundamen-
tally incurable [1, 2]. However, patients with recurrent
disease that is platinum-sensitive have a better response
rate and improved progression free survival (PFS) and
overall survival (OS) when treated with combination
therapy [2]. In patients with platinum-resistant disease,
single agent paclitaxel was shown to produce an object-
ive response rate of only 22–30 % [2]. In the case of pa-
tients with disease that is resistant to both platinum and
paclitaxel, other options are available, such as pegylated
liposomal doxorubicin (PLD), topotecan, and gemcita-
bine [2]; however, it is not always clear which patients
may benefit most from each therapy. Ultimately, al-
though multidrug regimens are associated with higher
toxicity, they are more effective than single agent therap-
ies. Gaining a better understanding of factors contribut-
ing to resistance to platinum and taxane based therapies
will be valuable in guiding treatment decisions for ovar-
ian cancer patients.
Human epididymis protein-4 (HE4/WFDC2) is a small
secretory protein that belongs to the family of whey
acidic protein (WAP) domain-containing anti-proteases
[3], and has been shown to possess cross-class anti-
protease activity itself [4]. It is overexpressed in ovarian
cancer tissues compared to normal ovaries, and has been
identified as a novel biomarker for EOC [5, 6]. Serum
levels predict ovarian cancer with equivalent sensitivity
to CA125, but with the advantage that HE4 is less fre-
quently elevated in patients with benign gynecological
conditions [5]. A multicenter study led by our institution
established a new algorithm for the diagnosis of women
with an ovarian mass [6]. The FDA-approved Risk of
Ovarian Malignancy Algorithm (ROMA) uses HE4 along
with CA125 and menopausal status to predict a woman’s
risk of ovarian cancer and monitor disease with im-
proved sensitivity and specificity over the Risk of Malig-
nancy Index (RMI) that used CA125, pelvic sonography,
and menopausal status [6].
Recently, HE4 has been associated with the develop-
ment of chemoresistance clinically. We have previously
determined that HE4 and ROMA scores are more sensi-
tive predictors of platinum response than CA125 alone
[7]. Angioli et al. reported that serum HE4 levels predict
platinum-resistant versus sensitive disease at the third
chemotherapy cycle with 100 % sensitivity and 85 %
specificity [8]. Similarly, another study found that serum
HE4 concentration is higher in patients resistant to first-
line chemotherapy [9]. Among high-grade serous ovarian
cancer (HGSC) patients, those whose HE4 levels displayed
greater reduction during neoadjuvant chemotherapy had
improved OS [10]. Collectively, these studies point to HE4
as a predictor of chemotherapy response/resistance, but
do not address the question of whether HE4 has a causa-
tive role in the development of resistance.
We have also shown that SKOV3 ovarian cancer cells
overexpressing HE4 are more resistant to cisplatin and
paclitaxel, while HE4-overexpressing OVCAR8 ovarian
cancer cells exhibit greater cisplatin resistance than their
null vector-transfected counterparts [7]. In mice, SKOV3
xenografts overexpressing HE4 also grew larger than
control SKOV3 xenografts [7]. In support of these data,
Wang et al. found that recombinant HE4-treated SKOV3
cells display reduced carboplatin-induced apoptosis, a
decreased ratio of BAX/BCL2, and an overall downregu-
lation of genes involved in DNA damage response and
apoptosis [11]. However, much remains to be elucidated
regarding how HE4 promotes resistance to platinum or
taxane therapies. Therefore, we sought first to confirm
our preliminary studies suggesting a causative role for
HE4 in cisplatin and paclitaxel resistance. Our second
goal was to examine the gene expression profile of
SKOV3 cells overexpressing HE4, as well as determine
differences in regulation of gene expression in response
to cisplatin treatment. Herein, we also begin to explore a




SKOV3 and OVCAR8 ovarian cancer cells were obtained
from American Type Culture Collection (Manassas, VA).
Cells were cultured in Dulbecco Modified Eagle Medium
(DMEM, Gibco, 11965-065) with 10 % fetal bovine serum
(FBS) and 1 % penicillin/streptomycin and kept in a 37 °C
humidified incubator with 5 % CO2.
Stable cell lines
All null vector (NV) and HE4-overexpressing stable cell
lines were previously established [7]. To generate HE4-
CRISPR Double Nickase stable cell lines, SKOV3-C1 cells
were transfected in 6-well plates with 1 μg HE4 Double
Nickase Plasmid (Santa Cruz, sc-402876-NIC) or Control
Double Nickase Plasmid (Santa Cruz, sc-437281), using
5 μl Lipofectamine 2000 (Invitrogen). After 48 h, media
was changed to 1 μg/ml puromycin containing media
for five days, then split into larger plates and selected
for an additional five days. RNA and tissue culture
supernatant was collected to confirm downregulation
of HE4 levels by quantitative RT-PCR (qRT-PCR) and
ELISA. Cells were maintained in DMEM supple-
mented with 10 % FBS, 1 % penicillin/streptomycin,
and 1 μg/ml puromycin.
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Cell treatments
Cells were treated with the described doses of cis-
diamminedichloroplatinum(II) (cisplatin, Sigma Aldrich,
1134357) or paclitaxel (Sigma Aldrich, T7402) dissolved
in dimethyl sulfoxide (DMSO, Sigma Aldrich, D8418), or
DMSO alone as a control. Cells were collected directly
into either Trizol (Ambion, 15596018) or Cell Lysis
Buffer (Cell Signaling, 9803) at the indicated time points for
analysis. Cells were treated with recombinant human HE4
(rHE4, MyBioSource, MBS355616) added directly to the
media to a final concentration of 20 nM. Cells were treated
with recombinant human epidermal growth factor (rEGF,
Calbiochem, 324831) at a concentration of 10 ng/ml.
Cell viability assays
All cells were seeded at 2 000 cells/well in 96-well plates.
Cells were treated with increasing doses of cisplatin and
paclitaxel as described. After 48 h, cell viability assays were
performed by adding 10 μl/well of CellTiter 96® Aqueous
One Solution Cell Proliferation MTS Assay (Promega,
G3580), incubating at 37 °C/5 % CO2 for 2 h, and reading
absorbance at 492 nm. Results are displayed as percent
survival of vehicle treated cells.
Microarray
SKOV3-NV and SKOV3-C1 cells were treated in tripli-
cate at 80 % confluency with 25 μM cisplatin or DMSO
vehicle. Total RNA was collected 24 h later using an
RNeasy Mini Kit (Qiagen, 74104) and checked for purity
by NanoDrop 2000 (Thermo Scientific). The RNA
samples were randomly assigned numbers and submitted
to the Brown Genomics Core Facility for Bioanalyzer
(Agilent 2100) RNA quality analysis. Affymetrix HTA 2.0
Arrays were performed according to the manufacturer’s
instructions at the Core Facility using 150 ng total input
RNA.
DAVID analysis
Database for Annotation, Visualization, and Integrated
Discovery (DAVID) v6.7 [12, 13] was used to identify the
top ten enriched annotation terms among 180 genes dif-
ferentially expressed (1.5-fold in either direction, p < .05)
between SKOV3-NV and SKOV3-C1. Default DAVID
parameters were employed as follows:
Kappa Similarity: Similarity Term Overlap – 3; Similarity
Threshold – 0.5
Classification: Initial Group Membership – 3; Final
Group Membership – 3; Multiple Linkage Threshold – 0.5
Enrichment Threshold: EASE – 1.0
Stringency: Medium
Quantitative PCR
RNA was collected using an RNeasy Mini Kit (Qiagen,
74104) or Trizol extraction/LiCl precipication. Total
RNA (500 ng) was reverse transcribed into cDNA using
the iScript cDNA Synthesis Kit (Bio-Rad, 1708890)
according the manufacturer’s protocol. To validate
differentially expressed genes between SKOV3-NV and
SKOV3-C1 cells identified by microarray, the same RNA
samples used for the microarray were employed. To val-
idate the differential cisplatin-induced upregulation of
EGR1 between SKOV3-NV and SKOV3-C1/C7, micro-
array RNA samples were used, as well as RNA isolated
from SKOV3-C7 cells that were treated in the same
manner as the cells used in the microarray. Quantitative
PCR was performed in triplicate by loading 1 μl cDNA
reaction, 2 μl each of 5 μM custom forward and reverse
primers (Invitrogen) or 1 μM forward and reverse vali-
dated primers (realtimeprimers.com), 10 μl SYBR Green
(Applied Biosciences [ABI], 4367659) and 5 μl RNAse-
free water to each well. Samples were run on an ABI
7500 Fast Real-Time PCR System, and data was analyzed
using the ΔΔCt method. Relative expression levels were
normalized to 18 s rRNA to correct for equivalent total
RNA levels. Validated MAPT, CYP1B1, and EGR1
primers were purchased from realtimeprimers.com.
Custom primer sequences (Invitrogen) are as follows:
AKT3 F – AAG GGA AGA ATG GAC AGA
AKT3 R – ATG GGT TGT AGA GGC ATC
NMUR2 F – CCG TTC CAC ATT GAC CGA CT
NMUR2 R – CAC CAC ATG GAC GAG GTT GA
SEPT3 F – TTG CCC TGC TTC GAG ACT TT
SEPT3 R – CTT TCC TCT GTG TCC ACG CT
18 s rRNA F – CCG CGG TTC TAT TTT GTT GG
18 s rRNA R – GGC GCT CCC TCT TAA TCA TG
Western blot
Protein was extracted from cell pellets in Cell Lysis
Buffer (Cell Signaling, 9803) with 1 mM PMSF, accord-
ing to the manufacturer’s protocol. Protein concentra-
tions were determined by DC Protein Assay (Bio-Rad
Laboratories, 5000116). Western blot analysis was
performed by loading equal amounts of protein boiled
with Novex Sample Reducing Agent (Life Technologies,
NP009) and NuPAGE LDS sample buffer (ThermoFisher
Scientific, NP0007) into a 4–12 % gradient NuPAGE
Novex Bis-Tris gel [Life Technologies, NP0321BOX
(mini), WG1402BX10 (midi)]. Protein was transferred by
semi-dry transfer to methanol-activated 0.2 μm PVDF
membranes (Bio-Rad, 162-0177) at 0.12-0.2 A for 1 h 15 m.
Membranes were blocked in 5 % milk in phosphate-
buffered saline with 0.05 % Tween 20 (PBS-T) for 30 m at
room temperature, incubated in primary antibody in 5 %
milk in PBS-T overnight at 4 °C, and then in secondary
antibody in 5 % milk in PBS-T for 1 h at room temperature,
with PBS-T washes in between. Amersham ECL Prime
Western Blot Detection System (GE Healthcare, RPN2232)
was used for detection of HRP-tagged secondary antibodies.
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Blots were developed using x-ray film in a Kodac film
developer or imaged directly in a Biorad Chemidoc MP
Imaging System. GAPDH was used as a loading control.
Antibodies and dilutions used are as follows:
PARP (Cell Signaling, 9532, 1:1000)
phospho-p44/42 MAPK (ERK1/2) (Cell Signaling, 4370,
1:2000)
p44/42 (ERK1/2) (Cell Signaling, 9102, 1:2000)
EGR1 (Santa Cruz, sc-110, 1:200)
p38 (Cell Signaling, 9212, 1:1000)
phospho-p38 (Cell Signaling, 9215, 1:1000)
GAPDH (Cell Signaling, 2118, 1:2000)
β-tubulin (Cell Signaling, 2146, 1:2000)
α-tubulin (Cell Signaling, 2144, 1:1000)
Densitometry
Image J was used to perform densitometry analysis of
western blots. Images of blots were analyzed in 8-bit
TIFF format, using the “analyze gel” function. Where no
band was detected, a value of “1” was assigned. Relative
band densities were normalized to a loading control, or
the appropriate total protein for phospho-proteins, and
then the lowest value was set to 1.
Statistics
In all instances where statistics are shown, they repre-
sent n ≥ 3 independent experiments, and p-values were
determined by unpaired 2-tailed Student t-test. For the
microarray, Affymetrix Transcriptome Analysis Console
(TAC) software was used to generate fold-changes and
statistical significance, and ANOVA p-values generated
by TAC were used for p-value cutoffs.
Results
HE4-overexpressing cells are more resistant to cisplatin
and paclitaxel treatment
Since HE4 serum levels correlate with cisplatin resist-
ance in ovarian cancer patients [7–10], and our previous
data suggested that HE4 promotes chemotherapy resist-
ance in vitro and in vivo [7], we set out to further define
the chemotherapy response of ovarian cancer cells that
overexpress HE4. We employed SKOV3 ovarian cancer
cells stably expressing a null vector plasmid (SKOV3-
NV) and two different clonally-selected cell lines stably
expressing a pCMV6-HE4 plasmid (SKOV3-C1 and
SKOV3-C7) [7]. SKOV3 cells are ideal to examine the
effects of HE4 overexpression since they secrete very
low levels of HE4 (<15 pM), as detected by ELISA [7].
We treated the cells with 0, 1.56, 3.125, 6.25, and
12.5 μM cisplatin or 0, 0.625, 1.25, 2.5, and 5 nM pacli-
taxel for 48 h, then performed MTS assays to measure
cell viability. SKOV3-C1 and SKOV3-C7 cells were
significantly more resistant than SKOV3-NV cells to
cisplatin (Fig. 1a) at 3.125 μM (p = .029 and .024,
respectively), 6.25 μM (p = .034 and 0.37, respectively),
and 12.5 μM (p = .0020 and .0018, respectively).
SKOV3-C1 and SKOV3-C7 cells were also more re-
sistant than SKOV3-NV cells to paclitaxel (Fig. 1b) at
1.25 nM (p = .017 and .083, respectively), 2.5 nM
(p = .0094 and .022, respectively) and 5 nM (p = .0050
and .0035, respectively).
In order to confirm that this resistance was due to in-
hibition in apoptosis, we analyzed the cleavage of poly
ADP ribose polymerase (PARP) in SKOV3-NV, SKOV3-
C1, and SKOV3-C7 cells treated with 5 μM cisplatin for
24, 48, and 72 h. Even in untreated cells, baseline levels
of cleaved PARP were lower in HE4-overexpressing
clones than in SKOV3-NV cells. In SKOV3-NV cells,
PARP cleavage was clearly increased by 5 μM cisplatin at
24 h, and continued to remain elevated at 48 h. By 72 h,
levels of cleaved PARP had diminished in SKOV3-NV
cells, presumably because most of the cells had already
undergone apoptosis. In HE4-overexpressing clones,
uncleaved PARP did accumulate to a similar degree as in
SKOV3-NV cells—suggesting that the cisplatin was able
to enter the cells and cause DNA damage, thus recruit-
ing PARP to sites of single-strand breaks. However,
cleavage of PARP did not occur in HE4-overexpressing
cells, indicating that the process of apoptosis was not
completed (Fig. 1c-d). We also observed an accumula-
tion in both PARP and cleaved PARP in SKOV3-NV
cells treated with 1 nM paclitaxel for 48 h, but did not
see this response as strongly in SKOV3-C1 or SKOV3-
C7 cells (Fig. 1e-f ). The fact that PARP did not accumu-
late robustly in HE4-overexpressing clones treated with
paclitaxel—unlike what we saw with cisplatin treatment—is
likely due to the vastly different mechanisms of action by
which these two drugs result in DNA damage.
Preliminary dose response experiments revealed that
OVCAR8 cells required high doses of cisplatin to
achieve cell death. Thus, we treated OVCAR8-NV and
HE4-overexpressing clones (OVCAR8-C5) with 0, 62.5,
125, 250, and 500 μM cisplatin for 24 h, and found a
slight increase in resistance in the OVCAR8-C5 cells
(Additional file 1A), which was also reflected by lower
levels of cleaved PARP in OVCAR8-C5 cells than
OVCAR8-NV cells treated with 100 μM cisplatin for
24 h (Additional file 1B-C). However, although OVCAR8
cells also secrete undetectable levels of HE4 as deter-
mined by ELISA (data not shown), they appear to
already be highly resistant to cisplatin and are not an
ideal model to examine the effects of HE4 on chemo-
therapy resistance. Likewise, OVCAR8-NV cells were
also more resistant to paclitaxel than SKOV3-NV cells,
and only exhibited a modest increase in resistance with
HE4 overexpression (Additional file 1D). For this reason,
we focused primarily on SKOV3 cells for the remainder
of our studies.
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CRISPR/Cas-mediated HE4 downregulation reduces
chemoresistance in SKOV3-C1 cells
In order to confirm that overexpression of HE4 was re-
sponsible for the increase in cisplatin resistance observed,
we knocked down HE4 in SKOV3-C1 cells by stable trans-
fection of a human HE4 CRISPR/Cas Double Nickase
plasmid. RNA from HE4-targeted cells (CRISPR-HE4) and
control plasmid transfected cells (CRISPR-Ctrl) was col-
lected to confirm effective targeting of the HE4 gene. Cell
culture supernatant was also collected and subjected to
ELISA to determine levels of secreted HE4 in the media.
CRISPR-HE4 transfected cells displayed 70.3 % knock-
down (p = .02) in HE4 mRNA levels compared to control
cells. Furthermore, CRISPR-HE4 media had undetectable
levels (<15 pM) of HE4, which is in agreement with what
we previously observed in SKOV3 wild type and SKOV3-
NV cells. HE4 concentration in CRISPR-Ctrl media mea-
sured 307 pM, which was comparable to our previously
reported levels for SKOV3-C1 and SKOV3-C7 cells
(250 pM and 362 pM, respectively) [7] (Fig. 2a). Next, we
measured survival of CRISPR-Ctrl and CRISPR-HE4 cells
in response to 25 μM cisplatin treatment (24 h), and
found that CRISPR-Ctrl cells exhibited 92.2 % cell survival
compared to vehicle-treated cells, while CRISPR-HE4 cells
displayed 81.9 % survival compared to vehicle-treated cells
(p = .005; Fig. 2b). Likewise, CRISPR-Ctrl cells exhibited
73.9 % survival in response to paclitaxel versus 65.9 %
survival of CRISPR-HE4 cells (p = .005) (Fig. 2c).
Microarray analysis reveals genes differentially regulated
by HE4 in ovarian cancer cells
In order to gain a better understanding of the differential
regulation of transcription between SKOV3-NV and
SKOV3-C1 cells in the presence and absence of cis-
platin, we performed a microarray analysis of total RNA




Fig. 1 HE4-overexpressing cells are more resistant to cisplatin and paclitaxel treatment. SKOV3-NV, SKOV3-C1, and SKOV3-C7 cells were treated with
0-12.5 μM cisplatin (a) or 0-5 nM paclitaxel (b) for 48 h, at which time the cells were subjected to MTS assay to measure viability. Results are displayed
as percent survival of vehicle treated cells. Error bars represent the standard deviation of biological replicates. *p < .05, **p < .005, N/S = not significant
(c) SKOV3-NV, SKOV3-C1, and SKOV3-C7 cells were treated with vehicle (DMSO) or 5 μM cisplatin, and protein was collected at 24, 48, and 72 h after
treatment. Western blot was performed to detect levels of PARP and cleaved PARP. d Densitometry analysis of PARP and cleaved PARP normalized to
GAPDH, from western blot in (c). e SKOV3-NV, SKOV3-C1, and SKOV3-C7 cells were treated with 1 nM paclitaxel and protein was isolated from all cells
(floating and adherent) 48 h after treatment. Western blot was performed to detect levels of PARP and cleaved PARP. GAPDH was used as a loading
control. f Densitometry analysis of PARP and cleaved PARP normalized to GAPDH, from western blot in (e)
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with either vehicle [dimethylsulfoxide (DMSO)] or
25 μM cisplatin for 24 h (n = 3/group). All transcripts
differentially regulated between groups 1.5-fold in either
direction (ANOVA p-value < .05) are available in
Additional file 2. The top fifteen annotated, protein-coding
genes that were differentially regulated in vehicle-treated
SKOV3-C1 cells compared to SKOV3-NV (p < .05) are
shown in Table 1. The Database for Annotation, Visual-
ization and Integrated Discovery (DAVID) [12, 13] was
used to perform gene ontology analysis of all genes differ-
entially expressed 1.5-fold in either direction (p < .05) in
SKOV3-C1 cells versus SKOV3-NV. This analysis revealed
enrichment for the terms “secreted glycoproteins”, “trans-
membrane domains”, “pregnancy and immunoglobulin-
like domains”, “cell adhesion”, “plasma membrane”, “fibro-
nectin”, “insulin-like growth factor binding”, “membrane
fraction”, “extracellular matrix”, and “EGF-like domains”
(Additional file 3). We validated four of the genes from the
list of most differentially expressed genes by quantitative
reverse-transcription PCR (qRT-PCR), as follows: V-Akt
Murine Thymoma Viral Oncogene Homolog 3 (AKT3);
septin 3 (SEPT3); cytochrome p450, family 1, subfamily B,
polypeptide 1 (CYP1B1); and neuromedin 2 (NMUR2)
(Fig. 3a-b).
Cisplatin-induced upregulation of EGR1 is suppressed in
HE4-overexpressing cells
The top fifteen annotated, protein-coding genes that
were differentially regulated between SKOV3-NV and
SKOV3-C1 cells in the presence of cisplatin are listed in
Table 2. This list excludes genes that were already differ-
entially regulated between SKOV3-NV and SKOV3-C1
A B
C
Fig. 2 CRISPR/Cas-mediated HE4 downregulation reduces chemoresistance in SKOV3-C1 cells. a SKOV3-C1 cells were transfected with a human
CRISPR-HE4 Double Nickase plasmid and CRISPR-Control Double Nickase plasmid for 48 h. Transfected cells were selected with puromycin and efficient
downregulation of HE4 was measured by qRT-PCR and ELISA. [HE4] = concentration of HE4 in supernatant as measured by ELISA. b-c CRISPR-Control
and CRISPR-HE4 cells were treated with DMSO vehicle or 25 μM cisplatin or 5 nM paclitaxel for 24 h, and MTS assay was performed to measure cell
viability. Results are displayed as percent survival of vehicle treated cells. Error bars represent the standard deviation of three or more
biological replicates, *p < .05
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vehicle treated cells. Of these genes, early growth re-
sponse 1 (EGR1), which is a key gene involved in regu-
lating growth and apoptosis in a wide variety of tissues,
presented as the most differentially expressed, with 4.07-
fold higher expression in SKOV3-NV than SKOV3-C1
(p = .000201). Silencing of EGR1 has been shown to pro-
mote resistance to cisplatin in esophageal cancer cells
[14], while overexpression of this gene sensitizes ovarian
cancer cells to cisplatin-induced apoptosis [15]. Thus,
we speculate that suppression of EGR1 upregulation
serves as a downstream effector of HE4-mediated cis-
platin resistance.
To further analyze genome-wide differences in cisplatin
response between SKOV3-NV and SKOV3-C1 cells, we
also conducted the following comparisons: SKOV3-NV
(vehicle vs. cisplatin) and SKOV3-C1 (vehicle vs. cis-
platin). The top fifteen differentially expressed annotated,
protein-coding genes in either direction are displayed in
Table 3. We also included EGR1 in this table, since it just
missed the cutoff as the sixteenth gene upregulated in
Table 1 Genes differentially expressed between SKOV3-NV and SKOV3-C1 (vehicle treated). SKOV3-NV and SKOV3-C1 cells were
treated with vehicle (DMSO) for 24 h (n = 3/group). RNA was isolated and Affymetrix HTA 2.0 arrays were performed to determine
differences in gene expression between SKOV3-NV and SKOV3-C1 cells. The top fifteen annotated, protein-coding genes (p < .05) in
either direction are listed below
Genes differentially expressed between SKOV3-NV and SKOV3-C1 (vehicle treated)
Gene symbol Description Fold change (NV/C1) ANOVA p-value
CYP1B1 Cytochrome P450, family 1, subfamily B, polypeptide 1 14.95 .000009
LAPTM5 Lysosomal protein transmembrane 5 12.8 2.58E-08
ANPEP Alanyl (membrane) aminopeptidase 12.09 1.27E-08
NMUR2 Neuromedin U receptor 2 11.96 .000004
EPHA7 EPH receptor A7 6.69 .000015
PKP2 Plakophilin 2 5.56 .000008
SLC43A3 Solute carrier family 43, member 3 5 .000012
ACSM3 Acyl-CoA synthetase medium-chain family member 3 4.62 .00002
POF1B Premature ovarian failure, 1B 3.98 .000026
CTH Cystathionase (cystathionine gamma-lyase) 3.76 .000036
ALPK2 Alpha-kinase 2 3.55 .000021
KCTD4 Potassium channel tetramerisation domain containing 4 3.47 .000099
EREG Epiregulin 3.42 .000006
DPP4 Dipeptidyl-peptidase 4 3.31 .000635
IL1A (interleukin 1, alpha) 3.19 0.000206
AKT3 v-akt murine thymoma viral oncogene homolog 3
(protein kinase B, gamma)
-4.03 .000163
RRAGD Ras-related GTP binding D -4.06 .000313
PSG3 Pregnancy specific beta-1-glycoprotein 3 -4.09 2.66E-07
POPDC3 Popeye domain containing 3 -4.18 .000124
SH3BGRL2 SH3 domain binding glutamic acid-rich protein like 2 -4.29 .000331
OLFM2 Olfactomedin 2 -4.33 .002074
DPYSL5 Dihydropyrimidinase-like 5 -4.48 .000457
SEPT3 Septin 3 -4.57 .000203
S1PR1 Sphingosine-1-phosphate receptor 1 -4.6 .000134
DSC3 Desmocollin 3 -5.13 .000179
GPC4 Glypican 4 -5.22 .000063
ADAM23 ADAM metallopeptidase domain 23 -5.53 .000245
PDE3B Phosphodiesterase 3B, cGMP-inhibited -6.63 .000081
PSG1 Pregnancy specific beta-1-glycoprotein 1 -6.73 .000064
CYP24A1 Cytochrome P450, family 24, subfamily A, polypeptide 1 -7.34 .000053
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SKOV3-NV cells by cisplatin, but not in SKOV3-C1.
Several other genes are represented in both Tables 2 and
3, including snail family zinc finger 1, (SNAI1), DNA-
damage-inducible transcript 3 (DDIT3), ADP-ribosylation
factor-like 14 (ARL14), and tumor necrosis factor (TNF).
Moreover, while there were several genes that were
cisplatin-regulated in both SKOV3-NV and SKOV3-C1,
the overall number of all transcripts regulated by cisplatin
(+/- 1.5-fold, p < .05) in SKOV3-NV was much greater
than in SKOV3-C1 cells (5935 vs. 1035), as represented by
comparative scatter plots (Additional file 4). Even among
those genes that were regulated in both SKOV3-NV and
SKOV3-C1 in Table 3, there tended to be a greater degree
of change in SKOV3-NV cells, especially for those genes
that were upregulated by cisplatin. These observations are
in agreement with the stronger cisplatin-response in
SKOV3-NV cells.
Because EGR1 was most the differentially expressed
gene between SKOV3-NV and SKOV3-C1 treated with
cisplatin, and has known roles in cisplatin response, we
validated its differential regulation by qRT-PCR using
SKOV3-NV, SKOV3-C1, and SKOV3-C7 RNA exposed
to vehicle (DMSO) or 25 μM cisplatin for 24 h (Fig. 4a).
Next, because EGR1 is an early response gene reported
to be upregulated as early as 15–30 min following expos-
ure to a stimulant [16, 17], we performed a time course
A
B
Fig. 3 Microarray qPCR validation. AKT3 and SEPT3 (a), and CYP1B1 and NMUR2 (b) were selected to validate microarray results by quantitative RT-
PCR. Error bars represent the standard deviation of three biological replicates, *p < .05, **p < .005
Ribeiro et al. Journal of Ovarian Research  (2016) 9:28 Page 8 of 18
analysis of EGR1 expression following cisplatin treatment
of SKOV3-NV and SKOV3-C1 cells. Interestingly, an early
upregulation of EGR1 occurred in both SKOV3-NV and
SKOV3-C1 cells beginning at 15 min after cisplatin treat-
ment, which peaked between 1 and 3 h post-treatment
and diminished by 6 h. However, the second more robust
increase in EGR1 expression observed at 24 h in SKOV3-
NV cells was dramatically suppressed in SKOV3-C1 cells
(Fig. 4b). A similar trend was noted in EGR1 protein
levels. While EGR1 protein was increased at 6 h in both
SKOV3-NV and SKOV3-C1 cells treated with 25 μM
cisplatin, only SKOV3-NV cells maintained higher levels
of EGR1 by 24 h (Fig. 4c-d). To confirm the intrinsic
ability of SKOV3-C1 cells to upregulate EGR1, both
SKOV3-NV and SKOV-C1 cells were treated with 10 ng/ml
human recombinant epidermal growth factor (rEGF) to
activate the EGFR signaling pathway, a known positive
regulator of EGR1 gene expression [18, 19]. We observed
a robust increase in EGR1 at 1 h after treatment in both
SKOV3-NV and SKOV3-C1 cells (Fig. 4c-d), which is in
Table 2 Genes differentially expressed between SKOV3-NV and SKOV3-C1 (Cisplatin Treated). SKOV3-NV and SKOV3-C1 cells were
treated with vehicle (DMSO) or 25 μM cisplatin for 24 h (n = 3/group). RNA was isolated and Affymetrix HTA 2.0 arrays were performed
to determine differences in gene expression between SKOV3-NV and SKOV3-C1 cells. The top fifteen protein-coding, annotated genes
with ≥1.5-fold change (p < 0.05) in either direction (excluding those genes that were already differentially expressed in vehicle treated
cells) are listed below
Genes differentially expressed between SKOV3-NV and SKOV3-C1 (Cisplatin Treated)
Gene symbol Description Fold change (NV/C1) ANOVA p-value
EGR1 Early growth response 1 4.07 .000201
GDF15 Growth differentiation factor 15 2.74 .00056
ARL14 ADP-ribosylation factor-like 14 2.72 .000978
HIST2H4B Histone cluster 2, H4b 2.63 0.005913
ZNF280A Zinc finger protein 280A 2.16 .003044
SNAI1 Snail family zinc finger 1 2.03 .003606
DDIT3 DNA-damage-inducible transcript 3 1.98 .000087
RND1 Rho family GTPase 1.91 .003688
IDI2 Isopentenyl-diphosphate delta isomerase 2 1.91 .004807
TNF Tumor necrosis factor 1.9 0.017979
ULBP2 UL16 binding protein 2 1.89 .001767
IL6 Interleukin 6 1.87 .000493
CCL20 Chemokine (C-C motif) ligand 20 1.86 0.000585
RAET1L Retinoic acid early transcript 1 L 1.84 0.000244
PPP1R15A (protein phosphatase 1, regulatory subunit 15A) 1.83 .001381
KDM6A (lysine (K)-specific demethylase 6A) -1.94 .006738
MYO9A Myosin IXA -1.94 0.002316
CCBE1 Collagen and calcium binding EGF domains 1 -1.94 0.001091
GLDC Glycine dehydrogenase (decarboxylating) -1.96 0.001179
RHOT1 Ras homolog family member T1 -1.96 0.001224
THBS1 Thrombospondin 1 -1.96 0.002038
APOO Apolipoprotein O -1.97 .001363
RNA5SP423 Ribosomal protein S6 kinase, 90 kDa, polypeptide 3 -2.05 .004154
RPS6KA3 Ribosomal protein S6 kinase, 90 kDa, polypeptide 3 -2.05 .004154
TBL1X Transducin (beta)-like 1X-linked -2.1 .002705
CDH6 Cadherin 6, type 2, K-cadherin (fetal kidney) -2.11 .00019
USP9X Ubiquitin specific peptidase 9, X-linked -2.12 .003764
PDK3 Pyruvate dehydrogenase kinase, isozyme 3 -2.17 .001499
BRWD3 Bromodomain and WD repeat domain containing 3 -2.27 .004584
ARL14EPL ADP-ribosylation factor-like 14 effector protein-like; laeverin -2.33 .002723
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Table 3 Genes Differentially Expressed Upon Cisplatin Treatment of SKOV3-NV and SKOV3-C1 Cells. SKOV3-NV and SKOV3-C1 cells were treated with vehicle (DMSO) or 25 μM cisplatin
for 24 h (n = 3/group). RNA was isolated and Affymetrix HTA 2.0 arrays were performed to determine cisplatin-induced differences in gene expression in SKOV3-NV and SKOV3-C1 cells.
The top fifteen annotated, protein-coding genes (p < 0.05) differentially expressed in either direction are listed below, as well as EGR1, which was the sixteenth gene change for
SKOV3-NV cells
SKOV3-NV-veh vs. SKOV3-NV-cis SKOV3-C1-veh vs. SKOV3-C1-cis
Gene symbol Description Fold-change ANOVA p-value Gene symbol Description Fold-change ANOVA p-value
PRKCA Protein kinase C, alpha 7.21 0.000002 PRKCA Protein kinase C, alpha 5.39 0.002139
SBF2 SET binding factor 2 6.27 4.50E-07 TMEM117 Transmembrane protein 117 5.24 0.001217
CDH6 Cadherin 6, type 2, K-cadherin (fetal kidney) 5.36 0.000009 PTPRG Protein tyrosine phosphatase, receptor type, G 5.22 0.000633
DYM Dymeclin 5.24 2.43E-07 PTPRM Protein tyrosine phosphatase, receptor type, M 4.89 0.000015
DPYD Dihydropyrimidine dehydrogenase 5.17 0.000011 MSI2 Musashi RNA-binding protein 2 4.79 0.013201
MSI2 Musashi RNA-binding protein 2 5.04 0.00001 CDKAL1 CDK5 regulatory subunit associated protein 1-like 1 4.69 0.005495
PTPRM Protein tyrosine phosphatase, receptor type, M 4.99 0.000004 DPYD Dihydropyrimidine dehydrogenase 4.61 0.001272
EXOC6B Exocyst complex component 6B 4.95 0.000001 PITPNC1 Phosphatidylinositol transfer protein, cytoplasmic 1 4.56 0.000222
CDKAL1 CDK5 regulatory subunit associated protein 1-like 1 4.9 0.000013 SBF2 SET binding factor 2 4.29 0.000294
TMEM117 Transmembrane protein 117 4.81 0.000003 SAMD12 Sterile alpha motif domain containing 12 4.19 0.004401
MAML2 Mastermind-like 2 (Drosophila) 4.78 0.000041 TENM1 Teneurin transmembrane protein 1 4.13 0.000457
SPTLC3 Serine palmitoyltransferase, long chain base subunit 3 4.76 0.000016 GTDC1 Glycosyltransferase-like domain containing 1 3.99 0.007196
PTPRG Protein tyrosine phosphatase, receptor type, G 4.67 9.73E-07 EXOC6B Exocyst complex component 6B 3.98 0.002653
TRHDE Thyrotropin-releasing hormone degrading enzyme 4.66 0.000011 CDH13 Cadherin 13, H-cadherin (heart) 3.83 0.000243
FTO Fat mass and obesity associated 4.57 2.54E-07 FTO Fat mass and obesity associated 3.69 0.009
EGR1 Early growth response 1 -3.51 0.000319 – – – –
FRG2 FSHD region gene 2; FSHD region gene 2-like -3.57 0.000156 SNAI1 (snail family zinc finger 1) -2.16 .000605
PPP1R15A Protein phosphatase 1, regulatory subunit 15A -3.69 0.000047 NR4A3 Nuclear receptor subfamily 4, group A, member 3 -2.17 0.00205
SNAI1 Snail family zinc finger 1 -3.85 0.00028 PMAIP1 Phorbol-12-myristate-13-acetate-induced protein 1 -2.22 2.51E-07
HBEGF Heparin-binding EGF-like growth factor -4.01 0.000148 FRG2 FSHD region gene 2; FSHD region gene 2-like -2.24 0.033969
NR4A3 Nuclear receptor subfamily 4, group A, member 3 -4.05 0.000145 GADD45A Growth arrest and DNA-damage-inducible, alpha -2.26 0.000042
TNFAIP3 Tumor necrosis factor, alpha-induced protein 3 -4.23 0.000031 CCL26 Chemokine (C-C motif) ligand 26 -2.37 0.023835
GADD45A Growth arrest and DNA-damage-inducible, alpha -4.23 0.000007 RND1 Rho family GTPase 1 -2.58 0.011645
DDIT3 DNA-damage-inducible transcript 3 -4.26 0.000017 TNFAIP3 Tumor necrosis factor, alpha-induced protein 3 -2.61 0.001029
ARL14 ADP-ribosylation factor-like 14 -4.28 0.000109 CCL20 Chemokine (C-C motif) ligand 20 -2.64 0.000022












Table 3 Genes Differentially Expressed Upon Cisplatin Treatment of SKOV3-NV and SKOV3-C1 Cells. SKOV3-NV and SKOV3-C1 cells were treated with vehicle (DMSO) or 25 μM cisplatin
for 24 h (n = 3/group). RNA was isolated and Affymetrix HTA 2.0 arrays were performed to determine cisplatin-induced differences in gene expression in SKOV3-NV and SKOV3-C1 cells.
The top fifteen annotated, protein-coding genes (p < 0.05) differentially expressed in either direction are listed below, as well as EGR1, which was the sixteenth gene change for
SKOV3-NV cells (Continued)
CCL20 Chemokine (C-C motif) ligand 20 -4.57 0.000051 HBEGF Heparin-binding EGF-like growth factor -2.96 0.000133
RND1 Rho family GTPase 1 -4.61 0.000069 ATF3 Activating transcription factor 3 -2.96 0.000575
ATF3 Activating transcription factor 3 -6.24 0.000007 IL1A Interleukin 1, alpha -3.36 0.00006
ZNF280A Zinc finger protein 280A -6.28 0.000082 ZNF280A Zinc finger protein 280A -3.78 0.000008












agreement with a previous study using the same dose
and time point [18]. These data indicate that HE4-
overexpressing cells are capable of upregulating EGR1,
but some mechanism is activated to suppress its later up-
regulation in response to cisplatin. Activation of ERK in
response to cisplatin and rEGF was comparable between
SKOV3-NV and SKOV3-C1 cells (Fig. 4c and e).
HE4 promotes deregulation of mitogen activated protein
kinase (MAPK) signaling
Because MAPKs transcriptionally activate EGR1 expres-
sion by phosphorylating the EGR1 transcription factor
ELK-1 [19–21], we assessed levels of phosphorylated
extracellular signal-regulated kinase (ERK) in SKOV3-NV,
SKOV3-C1, SKOV3-C7, OVCAR8-NV, and OVCAR8-C5
cell lines, and observed that levels of phospho-ERK were
higher in SKOV3 and OVCAR8 HE4-overexpressing
clones than in SKOV3-NV cells (Fig. 5a-b). In addition,
when SKOV3 wild type (WT) and OVCAR8-WT cells
were treated with 20 nM human recombinant HE4
(rHE4) protein, levels of phospho-ERK were dramatically
affected (Fig. 5c-d). In SKOV3-WT cells, phospho-ERK
was almost completely obliterated as early as 1 h after
treatment, but levels were restored to above baseline by
24 h. Conversely, phospho-ERK continuously increased
from 1 h to 24 h in OVCAR8-WT cells. These differential
results between SKOV3 and OVCAR8 cells suggest time-




Fig. 4 EGR1 mRNA and protein upregulation is suppressed in HE4-overexpressing clones. a Quantitative RT-PCR validation of microarray using
RNA from SKOV3-NV, SKOV3-C1, and SKOV3-C7 cells treated with vehicle (DMSO) or 25 μM cisplatin. Error bars represent standard deviation of
three biological replicates, *p < .05, **p < .005. b Timecourse analysis of EGR1 expression following treatment of SKOV3-NV and SKOV3-C1 cells with
25 μM cisplatin. c EGR1, phosphorylated ERK, and total ERK protein levels following treatment with vehicle (DMSO), 25 μM cisplatin, or 10 ng/mL
rEGF (positive control) were determined by western blot. GAPDH was used as a loading control. d-e Densitometry analysis of EGR1 (normalized
to GAPDH) and phospho-ERK/ERK ratio, from western blot in (c)
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factor signaling, but highlight the fact that HE4 has a rapid
and dramatic effect on kinase activation, which could in
turn affect regulation of EGR1 in response to cisplatin.
Although we see a significant effect of rHE4 on
phospho-ERK levels, we were unable to detect differences
in ERK activation between SKOV3-NV and SKOV3-C1 in
response to 6 h cisplatin treatment, as previously shown.
Moreover, by 24 h (the timepoint where we see the great-
est rise in EGR1), phospho-ERK levels are diminished in
both SKOV3-NV and SKOV3-C1 cells (Fig. 4c and e).
Since p38—another MAPK known to regulate EGR1 tran-
scription [20]—is also a key player in promoting apoptosis
in response to cisplatin, we examined levels of phospho-
p38 in SKOV3-NV and SKOV3-C1 clones following treat-
ment with 25 μM cisplatin for 1, 6, and 24 h. Interestingly,
p38 was robustly activated at 24 h in SKOV3-NV cells
following cisplatin treatment, but this response was
blunted in SKOV3-C1 cells (Fig. 5e-f). We also observed
similar results comparing p38 activation in SKOV3-NV,
SKOV3-C1, and SKOV3-C7 cells using a higher dose of
cisplatin (80 μM), with robust activation noted at 6 h only
in SKOV3-NV cells (Additional file 5A and B). We did ob-
serve a small suppression of ERK activation beginning at
1 h in HE4-overexpressing SKOV3 clones treated with
this high dose of cisplatin, which was most apparent at 6 h
after treatment, suggesting there may be subtle differences
in how ERK is activated in HE4-overexpressing clones that
only become apparent with high dose treatment
(Additional file 5A and C).
HE4 modulates tubulin levels and MAPT gene expression
One of the genes we found to be differentially expressed
between SKOV3-NV and SKOV3-C1 (vehicle treated) in
our microarray analysis was microtubule associated pro-
tein tau (MAPT). MAPT, which is associated with pacli-
taxel resistance in several cancers including EOC [22–28],
was more highly expressed in SKOV3-C1 cells than in




Fig. 5 HE4 promotes deregulation of mitogen activated protein kinase (MAPK) signaling. a Protein was collected from SKOV3-NV, SKOV3-C1, and
SKOV3-C7 cells and OVCAR8-NV and OVCAR8-C5 cells and western blot performed for phosphorylated ERK and total ERK. b Densitometry analysis
of phospho-ERK/ERK ratio, from western blot in (a). c SKOV3-WT and OVCAR8-WT cells were treated with 20 nM recombinant HE4 for the indicated
times, or left untreated. Protein was collected and western blot performed to determine levels of phosphorylated ERK and total ERK. d Densitometry
analysis of phospho-ERK/ERK ratio, from western blot in (c). e SKOV3-NV and SKOV3-C1 cells were treated with vehicle (DMSO) or 25 μM cisplatin for
the indicated times and western blot performed to detect levels of phospho-p38 and total p38. f Densitometry analysis of phospho-p38/p38 ratio,
from western blot in (e)
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We validated these results by qPCR, finding 4.42-fold
higher levels in SKOV3-C1 than SKOV3-NV (p = .00446)
(Fig. 6a). Since higher levels of MAPT together with β-
tubulin correlate with paclitaxel resistance in gastric can-
cer [23], we sought to determine if HE4 affects β-tubulin
levels and microtubule stability. Treatment of SKOV3-
WTand OVCAR8-WTcells with 20 nM rHE4 produced a
continuous increase in β-tubulin levels between 1 h and
48 h after treatment (Fig. 6b and c). Levels of α-tubulin
also increased over time, similar to what was seen with β-
tubulin (Fig. 6b and d). Collectively, these data suggest
that HE4 may in part promote paclitaxel resistance by
affecting microtubule levels or stability.
Discussion
The ways in which HE4 affects chemoresistance are
likely multi-factorial and cell type-specific. In cells that
already display a high degree of chemoresistance due to
other mechanisms, such as OVCAR8 cells, the effect of
increasing levels of HE4 may be minimal. In contrast, in
cells with low levels of HE4 that are not as chemoresis-
tant, increasing the level of HE4 may produce dramatic
changes in apoptotic response to drug treatment, as we
have observed in SKOV3 cells.
Human HE4 purified from seminal fluid has been de-
scribed to possess cross-class protease activity [4]; how-
ever, that study reports seminal fluid HE4 to exist as a
trimer migrating at 42 kDa under non-reducing condi-
tions and 14 kDa under SDS-PAGE reducing conditions.
It is possible that HE4 from different tissues may prefer-
entially exist in different forms, thus possessing different
functions. Indeed, in our lab, we observe HE4 migrating
on SDS-PAGE under reducing conditions as a 25 kDa
protein, which is in agreement with a study by Drapkin
et al. showing glycosylated HE4 migrating at 25 kDa in




Fig. 6 HE4 promotes tubulin deregulation in SKOV3 and OVCAR8 cells. a Quantitative RT-PCR of MAPT in SKOV3-NV and SKOV3-C1 cells, normalized to
18 s rRNA. **p < .05 b SKOV3-WT and OVCAR8-WT cells were left untreated or treated with 20 nM recombinant HE4, and protein was collected at the
indicated timepoints. Levels of β-tubulin and α-tubulin were determined by western blot, with GAPDH used as a loading control. c-d Densitometry
analysis of β-tubulin and α-tubulin, normalized to GAPDH, from western blot in (b)
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may result in different enzymatic activities of HE4. If
HE4 does modulate protease activity, it logically will
affect a wide variety of cellular functions, since proteases
are essential for many biological processes including
growth factor signaling. For example, hepatocyte growth
factor (HGF) [30], transforming growth factor beta
(TGFβ) [31], and certain members of the platelet-
derived growth factor (PDGF) family [32] are activated
by proteases. Our data would suggest that anti-proteases
may also serve a function in activating growth factor
cascades in some cases.
In our current study, we have observed a variety of dif-
ferences between SKOV3-NV and HE4-overexpressing
cells in how they respond to cisplatin and paclitaxel.
EGR1 is a transcription factor that is induced by a
variety of stimuli or stresses, including growth factors,
hormones, ionizing radiation, and chemotherapeutic
drugs [16, 19, 33–37]. It has been shown to regulate
differentiation, proliferation, and apoptosis in cell type-
specific manners by promoting expression of several
genes, including TP53 (p53), BCL2, PTEN, IGF2, PDGF,
VEGF, TGFB1, and TNF [18]. In our study, at 24 h after
cisplatin treatment, EGR1 is upregulated in SKOV3-NV
cells, but not in SKOV3-C1 or SKOV3-C7 cells. EGR1 is
a transcriptional regulator of growth differentiation fac-
tor 15 (GDF15) [38], which was also upregulated in
SKOV3-NV by cisplatin but not in SKOV3-C1 cells.
While GDF15 has been linked to platinum resistance in
pancreatic cancer [39] and ovarian cancer [40], it has
also been shown to be a common platinum-responsive
gene [41, 42], and was identified as a potential serum
marker for cisplatin-response of ovarian cancer cells [43].
Thus, the fact that it is not upregulated by cisplatin in
SKOV3-C1 cells is also indicative of their dampened cis-
platin resistance. Another gene, DNA-damage-inducible
transcript 3 (DDIT3), was also cisplatin-induced in
SKOV3-NV cells, but not SKOV3-C1 cells. Suppression of
DDIT3 mRNA upregulation has been shown to be
involved in chemoresistance of malignant pleural meso-
thelioma cells [44], further suggesting that multiple mech-
anisms may play a role in HE4-mediated chemoresistance.
Lastly, tumor necrosis factor (TNF), whose gene is also
EGR1-regulated [18], activates MAPKs and induces
apoptosis [45]; thus, its lack of cisplatin-mediated up-
regulation in SKOV3-C1 cells could also contribute to
suppression of pro-apoptotic signaling and cisplatin re-
sponse in these cells.
EGR1 gene expression is known to be regulated by
activated MAPKs, including phospho-ERK [19, 21] and
phospho-p38 [20]. Although we observe comparable in-
creases in phospho-ERK levels in SKOV3-NV and
SKOV3-C1 cells treated with 25 μM cisplatin, it is pos-
sible that HE4 affects the activity of phospho-ERK,
leading to suppression of EGR1. Indeed, our results
showing subtle suppression of ERK activation in HE4-
overexpressing clones treated with high dose cisplatin
(80 μM), as well as an effect of rHE4 on ERK activa-
tion in SKOV3-WT and OVCAR8-WT cells, support
this hypothesis. HE4-mediated suppression of p38 appears
to be more straightforward. We did not observe any effect
of rHE4 on phospho-p38 levels (data not shown), but we
did see more robust activation of p38 in SKOV3-NV cells
than in SKOV3-C1 or SKOV3-C7 cells in response to two
different doses of cisplatin (25 μM and 80 μM), confirm-
ing that some elements of MAPK signaling are deregu-
lated in HE4-overexpressing cells. This suppression of p38
activation could play a role in the suppression of cisplatin-
induced upregulation of EGR1.
Another significant effect that we report here is the in-
crease in α-tubulin and β-tubulin levels in SKOV3-WT
and OVCAR8-WT cells treated with rHE4. Interestingly,
tubulins have been reported to be the target of the serine
protease HtrA1 [46]; therefore, if HE4 inhibits serine
protease activity, tubulins may accumulate. We postulate
that the increase in tubulin levels we observe is not due
to a transcriptional effect, since we did not detect an in-
crease in any tubulin gene in OVCAR8-WT cells treated
with 20 nM rHE4 for 6 h (data not shown). However, as we
show here, we do see an increase in gene expression levels
of MAPT in SKOV3-C1 cells compared to SKOV3-NV,
which together with a putative stabilization of tubulin pro-
tein could influence paclitaxel resistance. Several lines of
evidence connect β-tubulin and MAPT to taxane resist-
ance. In addition to the correlation between MAPT and β-
tubulin III levels and paclitaxel resistance in gastric cancer
[23], downregulation ofMAPT was also shown to improve
taxane response in breast cancer cell lines [24] and in
ovarian cancer three-dimensional collagen I matrix culture
[22]. Clinically, expression of the tau protein is associated
with worse survival of taxane-treated breast cancer pa-
tients [28]. Since tau proteins are responsible for stabiliz-
ing microtubules [47], higher levels of MAPT could affect
the polymerization of microtubules by paclitaxel.
In addition to differences in how HE4-overexpressing
cells respond to cisplatin, intrinsic differences between
SKOV3-NV and SKOV3-C1 cells could also contribute to
resistance, or could indicate other biological functions of
HE4. For example, AKT3, which is more highly expressed
in SKOV3-C1 cells, has been shown to promote cisplatin
resistance in SKOV3 and OVCAR3 cells [48]. Another gene
of interest that is upregulated in SKOV3-C1 cells is SEPT3.
The septin family of GTP-binding proteins polymerize to
form cytoskeletal filaments [49], further implicating HE4’s
putative involvement in cytoskeleton organization. Several
genes that appear upregulated in HE4-overexpressing cells
are in agreement with the pro-proliferative role described
for HE4 [7, 11, 50], including AKT3, Ras-related GTP bind-
ing D (RRAGD), and glypican 4 (GPC4).
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Several other future directions remain to clarify how
HE4 promotes collateral resistance to platinum and tax-
ane therapies. Further clarification of precisely how HE4
affects cell signaling, including MAPK signaling, in
diverse cell lines is necessary. Confirmation of HE4’s
anti-protease function in ovarian cancer cells would be
useful in this regard. Moreover, additional information is
needed on how HE4 affects tubulin organization and
dynamics. Lastly, although we do not have any prelimin-
ary data to suggest that there are differences in drug
uptake or clearance between SKOV3-NV and SKOV3-C1
cells, it would be necessary to measure intracellular drug
levels at various time points post-treatment before ruling
this out as another contributing mechanism to chemore-
sistance. Future studies should also address whether HE4
promotes resistance to other commonly used ovarian can-
cer treatments such as doxorubicin.
Conclusions
In summary, we have demonstrated that HE4 promotes
collateral resistance to cisplatin and paclitaxel in SKOV3
and OVCAR8 ovarian cancer cells. Importantly, down-
regulating HE4 gene transcription using Double Nickase
CRISPR/Cas technology results in reduced secretion of
HE4 in SKOV3-C1 cells, and partially reverses chemoresis-
tance. In this study, we show that there are likely multiple
factors that contribute to HE4-mediated chemoresistance,
although two emerging factors that we present here for the
first time are deregulation of MAPK signaling and altered
tubulin dynamics. As we gain a better understanding of
how HE4 contributes to resistance to various chemother-
apies, monitoring HE4 levels before, during, and after
chemotherapy cycles may help predict responses and dic-
tate treatment decisions. Furthermore, small molecules or
antibodies targeting HE4 may enhance the efficacy of first-
or second-line therapeutics and reduce the development of
resistance.
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and paclitaxel in OVCAR8 cells. OVCAR8-null vector (NV) and OVCAR8-HE4
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activation of p38 and ERK. (A) SKOV3-NV, SKOV3-C1, and SKOV3-C7 cells
were treated with vehicle (DMSO) or 80 μM cisplatin for the indicated times.
Western blot was performed to detect levels of phospho-p38 and total p38.
(B) Densitometry analysis of p-p38/p38 ratio from (A). (C) Densitometry
analysis of phospho-ERK/ERK ratio from (A). (PPTX 443 kb)
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